Neoadjuvant immunotherapy with two drugs plus chemo for cervical cancer
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests two immunotherapy drugs (iparomlimab and tuvonralimab) combined with chemotherapy before surgery for locally advanced cervical cancer. It aims to shrink tumors and improve outcomes for patients who haven't had prior systemic treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 70 years old.
- You must have a type of cervical cancer called squamous cell, adenocarcinoma, or adenosquamous carcinoma, at stage IB3, IIA2, or IIIC1r.
- You should not have received chemotherapy or other systemic treatment for your cancer yet.
- You need to have good organ function and be in good overall health (ECOG score 0 or 1).
- You must be willing to provide blood and tumor tissue samples for testing.
- You cannot have other active cancers, serious infections, or autoimmune diseases needing treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two immunotherapy drugs with standard chemotherapy before surgery for cervical cancer that has not spread far. The goal is to shrink the tumor and improve treatment outcomes.
This trial tests adding a new immunotherapy drug (cadonilimab) to standard chemotherapy before surgery for locally advanced cervical cancer. The goal is to see if this combination helps shrink the tumor more effectively before surgery.
This trial tests whether a combination of chemotherapy and immunotherapy (pembrolizumab) before surgery works better than standard chemoradiation for locally advanced cervical cancer. It may help shrink tumors more effectively.
This trial tests two immune-boosting drugs (iparomlimab and tuvonralimab) combined with standard chemotherapy given before surgery for locally advanced cervical cancer. The goal is to shrink the cancer and improve survival chances.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) with standard chemoradiation for locally advanced cervical cancer caused by HPV. It may be an option for women with stage 3-4A disease or positive lymph nodes who have not had immunotherapy before.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus standard chemotherapy before surgery for cervical cancer. The goal is to see if this treatment can shrink the tumor and improve outcomes, and it is given as a neoadjuvant (before-surgery) approach.
Hear when a new Locally Advanced Cervical Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.